Yanyan Tudor
Amgen (United States)(US)
Publications by Year
Research Areas
Pancreatic and Hepatic Oncology Research, Colorectal Cancer Treatments and Studies, Synthesis and biological activity, Quinazolinone synthesis and applications, Cancer, Hypoxia, and Metabolism
Most-Cited Works
- → Discovery of Aminoquinazolines as Potent, Orally Bioavailable Inhibitors of Lck: Synthesis, SAR, and in Vivo Anti-Inflammatory Activity(2006)67 cited
- → Putative Predictive Biomarkers of Survival in Patients with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine and Ganitumab, an IGF1R Inhibitor(2013)66 cited
- → Structure-Based Design of Novel 2-Amino-6-phenyl-pyrimido[5′,4′:5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as Potent and Orally Active Inhibitors of Lymphocyte Specific Kinase (Lck): Synthesis, SAR, and In Vivo Anti-Inflammatory Activity(2008)63 cited
- → Novel 2-Aminopyrimidine Carbamates as Potent and Orally Active Inhibitors of Lck: Synthesis, SAR, and in Vivo Antiinflammatory Activity(2006)61 cited
- → Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase(2005)48 cited
- → Discovery of Aryl Aminoquinazoline Pyridones as Potent, Selective, and Orally Efficacious Inhibitors of Receptor Tyrosine Kinase c-Kit(2008)46 cited
- → 3-Amino-7-phthalazinylbenzoisoxazoles as a Novel Class of Potent, Selective, and Orally Available Inhibitors of p38α Mitogen-Activated Protein Kinase(2008)26 cited
- → Structure-Guided Design of Aminopyrimidine Amides as Potent, Selective Inhibitors of Lymphocyte Specific Kinase: Synthesis, Structure–Activity Relationships, and Inhibition of in Vivo T Cell Activation(2008)22 cited
- → High-Throughput Implementation of the NanoBRET Target Engagement Intracellular Kinase Assay to Reveal Differential Compound Engagement by SIK2/3 Isoforms(2019)19 cited
- → High-Content Screening Analysis of the p38 Pathway: Profiling of Structurally Related p38 α Kinase Inhibitors Using Cell-Based Assays(2006)19 cited